Relmada Therapeutics Inc

Research Relmada Therapeutics Inc (RLMD) on Bullrun: market cap USD 732.13M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRLMD
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 732.13M
• Financial periodFY2025

Valuation Snapshot

latest market cap is USD 732.13M.

About Relmada Therapeutics Inc

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer;

Frequently asked questions

What is Relmada Therapeutics Inc's market cap?

Relmada Therapeutics Inc's market capitalization is USD 732.13M.

What does Relmada Therapeutics Inc do?

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of...